View Older Stories View More Recent Stories

Oct 29, 2019 04:02PM Seattle Genetics Reports Third Quarter 2019 Financial Results
Oct 21, 2019 06:46AM Seattle Genetics (SGEN) Announces Positive Topline Results from Pivotal Trial of Tucatinib in Locally Advanced or Metastatic HER2-Positive Breast Cancer
Oct 21, 2019 06:45AM Seattle Genetics Announces Positive Topline Results from Pivotal Trial of Tucatinib in Locally Advanced or Metastatic HER2-Positive Breast Cancer
Oct 10, 2019 08:00AM Seattle Genetics Announces Initiation of Phase 3 Clinical Trial of Tucatinib in Combination with Ado-trastuzumab Emtansine (T-DM1, Kadcyla®) for Patients with Advanced or Metastatic HER2-Positive Bre
Oct 8, 2019 08:00AM Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2019 Financial Results on October 29, 2019
Sep 29, 2019 09:00AM Initial Results from MOUNTAINEER Trial Show Antitumor Activity of Tucatinib Combination in HER2-Positive Metastatic Colorectal Cancer
Sep 28, 2019 02:30AM Seattle Genetics and Astellas Announce Results from Phase 1 Trial of Investigational Agent Enfortumab Vedotin in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Blad
Sep 28, 2019 02:30AM Seattle Genetics and Astellas Announce Results from Phase 1 Trial of Investigational Agent Enfortumab Vedotin in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Blad
Sep 17, 2019 08:09AM Seattle Genetics (SGEN) Announces Presentations of New Clinical Data from Multiple Studies of Novel Targeted Therapies at ESMO
Sep 17, 2019 08:00AM Seattle Genetics Announces Presentations of New Clinical Data from Multiple Studies of Novel Targeted Therapies at the European Society for Medical Oncology (ESMO) 2019 Congress
Sep 16, 2019 08:02AM Seattle Genetics (SGEN), Astellas Pharma Inc. Granted FDA Priority Review for Enfortumab Vedotin Biologics License Application
Sep 16, 2019 08:00AM Seattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
Sep 16, 2019 08:00AM Seattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
Jul 16, 2019 04:02PM Seattle Genetics Reports Second Quarter 2019 Financial Results
Jul 16, 2019 08:04AM Seattle Genetics (SGEN), Astellas Announce Submission of BLA to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
Jul 16, 2019 08:00AM Seattle Genetics and Astellas Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
Jul 16, 2019 08:00AM Astellas and Seattle Genetics Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
Jul 2, 2019 08:00AM Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2019 Financial Results on July 16, 2019
Jun 12, 2019 08:00AM Seattle Genetics Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentations at the Congress of the European Hematology Association (EHA) and the International Conference on Malignant Lymphoma (
Jun 10, 2019 12:51PM Seattle Genetics’ Antibody-Drug Conjugate Technology Utilized in Genentech’s Polivy, Now Approved by FDA
Jun 3, 2019 08:03AM Seattle Genetics (SGEN) Highlights Additional Analyses of ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials of ADCETRIS at ASCO 2019 Meeting
Jun 3, 2019 08:00AM Seattle Genetics Announces Additional Analyses of ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials of ADCETRIS® (Brentuximab Vedotin) at the 2019 ASCO Annual Meeting
Jun 3, 2019 07:32AM Seattle Genetics (SGEN), Astellas Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Canc
Jun 3, 2019 07:30AM Seattle Genetics and Astellas Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer
Jun 3, 2019 07:30AM Astellas and Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer
May 21, 2019 08:00AM Seattle Genetics Appoints Robin Taylor, Ph.D., Chief Commercial Officer
May 15, 2019 05:10PM Seattle Genetics Announces Presentations of New Clinical Data from Multiple Studies of Novel Targeted Therapies at the American Society of Clinical Oncology (ASCO) Annual Meeting
May 15, 2019 08:00AM Seattle Genetics to Present at RBC Capital Markets 2019 Global Healthcare Conference
May 3, 2019 12:09PM Seattle Genetics Announces Progress in Expanding ADCETRIS® (Brentuximab Vedotin) Indications in Canada
Apr 25, 2019 04:02PM Seattle Genetics Reports First Quarter 2019 Financial Results
Apr 4, 2019 08:00AM Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2019 Financial Results on April 25, 2019
Mar 29, 2019 08:06AM Seattle Genetics (SGEN) Reports Complete Enrollment in Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
Mar 29, 2019 08:00AM Seattle Genetics Completes Enrollment in Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
Mar 28, 2019 07:00AM Seattle Genetics to Host Conference Call on Positive Topline Results from Pivotal Trial of Enfortumab Vedotin
Mar 28, 2019 05:56AM Seattle Genetics (SGEN), Astellas Pharma Inc. Report Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
Mar 28, 2019 03:01AM Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
Mar 28, 2019 03:01AM Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
Mar 27, 2019 08:00AM Seattle Genetics Highlights Antibody-Drug Conjugate Innovation and Immuno-Oncology Program at the American Association for Cancer Research (AACR) Annual Meeting
Mar 5, 2019 08:00AM Seattle Genetics to Present at Cowen and Company 39th Annual Health Care Conference
Feb 11, 2019 08:01AM Seattle Genetics (SGEN) chieves $30 Million Milestone Payment for EC Approval of ADCETRIS in Frontline Hodgkin Lymphoma
Feb 11, 2019 08:00AM Seattle Genetics Achieves $30 Million Milestone Payment for European Commission Approval of ADCETRIS® (Brentuximab Vedotin) in Frontline Hodgkin Lymphoma
Feb 7, 2019 04:02PM Seattle Genetics Reports Fourth Quarter and Full Year 2018 Financial Results
Feb 6, 2019 08:00AM Seattle Genetics to Present at Guggenheim Healthcare Talks Idea Forum | Oncology Day
Jan 22, 2019 08:00AM Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2018 Financial Results on February 7, 2019
Jan 9, 2019 08:03AM Seattle Genetics (SGEN) Reports Publication of North American Subgroup Data from ECHELON-1 Phase 3 Clinical Trial of ADCETRIS (Brentuximab Vedotin) in Newly Diagnosed Advanced Hodgkin Lymphoma
Jan 9, 2019 08:00AM Seattle Genetics Announces Publication of North American Subgroup Data from ECHELON-1 Phase 3 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Advanced Hodgkin Lymphoma
Dec 19, 2018 08:00AM Seattle Genetics to Present at the J.P. Morgan Healthcare Conference
Dec 4, 2018 05:51AM Seattle Genetics (SGEN), Takeda Report Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS (Brentuximab Vedotin)
Dec 3, 2018 09:15PM Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas
Dec 3, 2018 06:13AM Seattle Genetics (SGEN) Provides Additional Analyses from ECHELON-1 Phase 3 Clinical Trial of ADCETRIS (Brentuximab Vedotin) in Newly Diagnosed Advanced Hodgkin Lymphoma
View More Recent Stories View Older Stories